In the presence of the inhibitor, BMAL1 and PPARa oscillations were found to be fine-tuned in AML and CLL (Figure 5) patient samples when compared to non-treated patient samples (Figure 4). This evidence concerns the gene BMAL1 and acute myeloid leukemia.